Cytoguide ApS cytoguide.dk


Public lists: Pharma Startups (4732)

CytoGuide focuses on the development of two-component drugs that has the potential to maximise the effectiveness of a well-known Rheumatoid Arthritis treatment while drastically minimising its side effects.

CytoGuide focuses on the development of two-component drugs that has the potential to maximise the effectiveness of a well-known Rheumatoid Arthritis treatment while drastically minimising its side effects.

Company (Alive / Active)

Phone: 458-620-5294

Fax: 458-613-1160

INCUBA Science Park
Gustav Wieds Vej 10
DK 8000
Denmark

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cytoguide ApS $0M Nov 30, 2018
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cytoguide ApS Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Labopharm

Laval, Quebec, Canada
Alive / ActiveLabopharm is an international, specialty pharmaceutical company that develops improved formulations of currently marketed drugs using the Company's advanced, controlled-release technologies. Labopharm's strategy is to leverage these technologies to develop and commercialize new formulations of existing products that address the market's preference for drugs that offer simplified dosing regimens, improved efficacy or a reduced side effect profile.Login to see details

Atherogenics

Alpharetta, Georgia, United States
Alive / ActiveAtheroGenics is an emerging pharmaceutical company, focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as heart disease (atherosclerosis), asthma and arthritis. Based on a proprietary drug discovery technology platform called vascular protectant technology, the company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the blood vessels of the...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Agents, uses and methods Dec 01, 2016 Application